Other News Items

Research Agreement Signed with Cerveau Technologies


Cerveau Technologies Inc. signed an agreement with the MGH Gordon Center to support multiple projects over the next several years. These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.

As part of the agreement, Cerveau will contract with the Gordon Center for Medical Imaging, a research center and PET imaging facility within MGH, to manufacture and supply the [18F]MK-6240 needed for initiatives in the greater Boston area. “We are glad to be part of the effort to make Tau PET available to the New England research community as it is becoming a tool of choice for in vivo assessment of tau pathology in many brain disorders,” said Dr. Georges El Fakhri, Director of the MGH Gordon Center.

According to Dr. Keith Johnson, leader of the Aging NeuroImaging Program at the MGH Gordon Center, and the Harvard Aging Brain Study, “the ability to detect tau brain pathology in living humans is a major medical breakthrough. The value of this novel technology has already been demonstrated to improve the likelihood we can develop treatments for Alzheimer’s disease. In addition, however, brain tau deposition is a major player in chronic traumatic encephalopathy, fronto-temporal dementia, and several forms of Parkinsonism. This means that successful research program initiatives for novel radio-pharmaceuticals such as MK6240 are an important advance toward refinement and optimization of tau PET, which is the rapidly developing biomarker technology aimed at tracking tau pathology in a variety of brain disorders.”

“Cerveau welcomes this opportunity to work with the MGH researchers, who have a very successful history of leadership in this field to understand the application of MK-6240 and how it may benefit patients with brain diseases. The collaboration with the Gordon Center at MGH will also provide access to our pharmaceutical partners in support of various therapy trials and support our global production network in Europe, Canada, Japan, China, Singapore, Australia and the United States as well facilitate novel research at MGH in the pursuit of evaluating potential preventive treatment options for Alzheimer’s disease,” said Rick Hiatt, President and CEO of Cerveau Technologies, Inc.

Read more: https://www.businesswire.com/news/home/20180208005974/en

Brain PET scan

2018 Gordon Center Winter Holiday Party


A warm thank you to everyone who joined us for our winter holiday party.

2018 Human Amyloid Imaging Conference


The 12th Human Amyloid Imaging Conference took place in Miami, Florida on January 17-19, 2018.

Dr. Keith Johnson organized the event with the help of Drs. Bill Klunk (University of Pittsburgh), Chet Mathis (University of Pittsburgh) and Bill Jagust (University of California, Berkeley).

This year’s conference featured two cross-disciplinary keynote speakers: Drs. William Seeley (University of California, San Francisco) and Peter Davies (Northwell Health). They discussed what the presence of brain amyloid means, how it should be measured, how it changes, and what it signifies.

The 2018 meeting included podium and poster presentations on cutting edge research into biomarkers for Alzheimer’s-related disease. It drew more than 400 attendees and showcased 130 posters from research groups spanning North America, Europe, East Asia, and Australia.

For more information, please see the Human Amyloid Imaging Conference website.

Poster Presentations at the 2018 Human Amyloid Imaging Conference

Annual Holiday Party


Thank you to everyone who made it out to our annual holiday party. Take a look at the gallery below for some of the highlights of the evening.

Happy Holidays


For the upcoming holidays, we will be closed Monday, December 26, and Monday, January 2. We wish you a healthy and happy holiday season!

Happy Holidays & Best Wishes for the New Year

PET Production Facility


The production facility is a cGMP/FDA registered PET drug manufacturer that consists of an ISO Class 8 manufacturing area, an ISO Class 7 cleanroom and a quality control lab. The core laboratories are equipped with over 20 mini cells and automated chemistry modules used primarily for the synthesis of 18F, 11C and 13N radiopharmaceuticals.

Click on video for more Dr. Daniel Yokell giving an overview of the facility

Dr. Quanzheng Li Promoted to Associate Professor


We are pleased to announce Dr. Quanzheng Li's promotion to Associate Professor at Harvard Medical School. Dr. Li received his doctoral degree in Electrical Engineering in 2005 from the University of Southern California before joining Masschusetts General Hospital in 2011. He has published several works on image reconstruction and kinetic modeling, and is the recipient of several honors including the IEEE-NPSS Early Achievement Award.

Dr. Quanzheng Li

Dr. Quanzheng Li

Molecular Imaging Pushes Boundaries of Personalized Medicine


Researchers at the Gordon Center for Medical Imaging are using molecular imaging and nuclear medicine technology to push the boundaries of personalized medicine. We talked to Dr. Rachid Akiki, MD, who is working closely with Dr. Marc Normandin, PhD, in the Gordon Center of the Radiology Department, to find out how.

What is molecular imaging?

Molecular imaging provides detailed pictures of what’s happening inside the body at the smallest level, cells and molecules. Using tracers to illuminate cellular activity, molecular imaging can reveal how a cell behaves and help us understand disease progression. Molecular imaging can confirm a diagnosis, monitor and assess the effectiveness of a treatment like chemotherapy. It is the basis upon which pharmacological companies create new drugs.

How does molecular imaging help you research disease?

We commonly use MRI, CT and PET to take a closer look at the behavior of cells affected by diseases such as cancer, diabetes, heart and kidney problems. Using a small amount of PET tracer, molecular imaging can help improve the ways we diagnose and treat a disease on a case-by-case basis. Cancer cells, for instance, can form unique structures and behave differently from patient to patient.

Tell us about a recent project?

Our new microscope is unique in that it can be used to do single cell PET instead of whole body imaging. This scaled down modality (10s of microns) allows to better understand what we typically image at the whole body, 1cm scale, and possibly assess how cells respond to treatment and compare their behaviors with normal cells under different circumstances. Innovations like these, combined with data on cellular activity, are the foundation of personalized medicine.

Tell us about yourself?

I am 26 years old and have studied physics at AUB, medicine and medical imaging at BU. Currently I work as a postdoctoral research fellow at Massachusetts General Hospital with an appointment at Harvard medical school on nuclear medicine research topics and their applications in medicine. I like very much my research work and I hope I can affect positively the lives of people significantly while advancing the science. I look forward to start my clinical residency in 2016 and translate my research work to the clinical setting.

This article was originally posted by Massachusetts General Hospital Imaging on Wednesday, January 20, 2016